Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• January 2022

The largest GWAS meta-analysis conducted to date associating SNPs to venous thromboembolism in children and adolescents treated on childhood ALL protocols ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• May 2020

The prognosis for high-risk childhood acute leukaemias remains dismal and established treatment protocols often cause long-term side effects in survivors. This study aims to identify more effective and safer therapeutics for these patients. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• April 2021

Pineoblastoma is a rare brain tumor usually diagnosed in children. Given its rarity, no pineoblastoma-specific trials have been conducted. Studies have included pineoblastoma accruing for other embryonal tumors over the past 30 years. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• April 2022

GATA3low ETP-ALL is a novel stem cell-like leukemia with implications for the use of myeloid-derived therapies ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2016
• September 2016

Medulloblastoma is the most common form of malignant paediatric brain tumour and is the leading cause of childhood cancer related mortality. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2014
• November 2014

Acute Lymphoblastic Leukemia (ALL) occurring in the first year of life is rare. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• September 2012

This study contributes to our understanding of the genetic diversity of NMC, an important step towards finding therapeutic targets for a disease that is... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• November 2012

Rishi Sury Laurence Sébastien Kotecha Cheung Malinge RS LC SM MB ChB (Hons) MRCPCH FRACP PhD BPharm (Hons) MBA PhD PhD Co-Head, Leukaemia Translational Research Co-Head, Leukaemia Translational Research Laboratory Head, Translational Genomics in ...

• 1. Telethon Kids Institute
• Projects

KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we perform RNA sequencing, methylation array analysis, whole exome and targeted deep sequencing on 84 infants with KMT2A-rearranged leukemia. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• August 2022

Invasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups are poorly defined. Retrospective national multicenter cohort data (2004-2013) were analyzed to document prevalence, clinical characteristics, and microbiology of IFD. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2024
• April 2024

Pediatric acute lymphoblastic leukemia (ALL) therapy is accompanied by treatment-related toxicities (TRTs) and impaired quality of life. In Australia and New Zealand, children with ALL are treated with either Children's Oncology Group (COG) or international Berlin-Frankfurt-Munster (iBFM) Study Group-based therapy. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• September 2022